Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jonathan Dore

Physician Assistant Clifton Park, NY Physician Assistant

NPI 1750887329 CMS profile 10593405

939 Route 146 Ste 700, Clifton Park, NY 12065

Open in the dashboard

General payments

$5,698

323 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jonathan Dore of Clifton Park, NY is reported in the CMS Open Payments database as having received $5,698 across 323 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $820 46
2024 General $1,261 70
2023 General $1,203 63
2022 General $1,076 61
2021 General $1,337 83

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jonathan Dore
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Jonathan Dore were reported at $820. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Jonathan Dore Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,337 $132 $37–$438 $132
2022 $1,076 $155 $48–$522 $149
2023 $1,203 $167 $52–$557 $160
2024 $1,261 $178 $55–$600 $164
2025 $820 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $823 58 payments
  2. Novo Nordisk Inc $724 41 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $488 23 payments
  4. AstraZeneca Pharmaceuticals LP $456 25 payments
  5. Amgen Inc. $395 22 payments
  6. GlaxoSmithKline, LLC. $368 23 payments
  7. Abbott Laboratories $320 17 payments
  8. Lilly USA, LLC $295 15 payments
  9. Pfizer Inc. $256 17 payments
  10. Astellas Pharma US Inc $150 7 payments
  11. Other $1,423 75 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,698 323 payments
Products named General payments · program years 2021–2025
  1. RYBELSUS $452 26 payments
  2. Ozempic $443 26 payments
  3. JARDIANCE $442 21 payments
  4. UBRELVY $410 33 payments
  5. QULIPTA $389 28 payments
  6. Otezla $267 14 payments
  7. TRELEGY ELLIPTA $241 16 payments
  8. NURTEC ODT $233 13 payments
  9. FARXIGA $218 11 payments
  10. FreeStyle Libre 3 $209 11 payments
  11. Other $4,546 253 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 76 drugs

Part D claims

3,396

Median for Physician Assistant: 241

Drug cost

$329,334

Median for Physician Assistant: $4,110

Branded share of claims

18.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 63 $71,679
Ozempic Semaglutide Brand 39 $65,982
Eliquis Apixaban Brand 52 $41,307
Farxiga Dapagliflozin Propanediol Brand 37 $29,153
Rybelsus Semaglutide Brand 21 $26,397
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 22 $15,966
Mounjaro Tirzepatide Brand 11 $11,394
Myrbetriq Mirabegron Brand 17 $10,755
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 11 $6,907
Atorvastatin Calcium Generic 308 $3,926

The 10 drugs with the highest cost, of 76 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$33,296

Of which drugs: $4,100

Medicare patients

126

Average age 73

Services billed

1,196

21 women, 105 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Ischemic heart disease 41%
Arthritis 27%
Diabetes 23%
Chronic kidney disease 17%
Cancer 17%
Atrial fibrillation 16%
Depression 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 30 30 $2,455

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $117
$117 37 —
VRAYLAR
  • AbbVie, Inc. $116
$116 — —
MOUNJARO
  • Lilly USA, LLC $110
$110 11 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $76
$76 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $73
$73 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

323 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record